Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,180.00 Price Target at Guggenheim

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by Guggenheim from $1,040.00 to $1,180.00 in a research report sent to investors on Thursday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on the stock. Cantor Fitzgerald reaffirmed a neutral rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a buy rating in a research note on Wednesday, April 24th. Evercore ISI started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an outperform rating and a $1,150.00 price target for the company. Truist Financial reiterated a buy rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, Canaccord Genuity Group restated a buy rating and issued a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $1,063.82.

Regeneron Pharmaceuticals Trading Down 0.3 %

Regeneron Pharmaceuticals stock opened at $1,063.60 on Thursday. The stock has a 50-day moving average price of $1,025.07 and a 200 day moving average price of $972.23. The company has a market capitalization of $117.20 billion, a price-to-earnings ratio of 31.42, a price-to-earnings-growth ratio of 2.20 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals has a 52 week low of $720.00 and a 52 week high of $1,106.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.12 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph J. Larosa sold 1,866 shares of the company’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the transaction, the executive vice president now owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. Over the last three months, insiders have sold 65,074 shares of company stock worth $64,546,123. 7.48% of the stock is owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently made changes to their positions in REGN. West Paces Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the period. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at approximately $28,000. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth $31,000. MCF Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the last quarter. Finally, Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.